Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction

Abstract

The impact of psoriasis on quality of life has been studied in select patient populations. Population-based data detailing the distribution of extent of disease, associated problems in everyday life, and treatment satisfaction for the US population have been lacking. Our population-based survey indicates that approximately 4.5 million adults have been diagnosed as having psoriasis. Most (59%) have little or no involvement, but 650,000 adults have at least three palms of body surface involved and more than 1,000,000 indicate substantial dissatisfaction with their treatment. Only 5% of patients (56,000) who report severe dissatisfaction with current therapy have extensive disease (10 palms). Many individuals with little psoriasis at the time of interview considered the disease to be a large problem in everyday life.

Clinical and Epidemiological Features of Psoriasis in Patients Visiting Lumbini Medical College

“…One should understand that the treatment is a control rather than cure. [3][4][5][6] The current study presents the clinical and epidemiological features of psoriatic patients attending the dermatology Outpatient department of Lumbini Medical College Teaching Hospital, which is a 700 bedded multi-specialty hospital in the semiurban area of Lumbini, Nepal.…”

Dual Inhibition of TNFR1 and IFNAR1 in Imiquimod-Induced Psoriasiform Skin Inflammation in Mice

“…The Journal of Immunology, 2015, 194: 5094-5102. P soriasis is a chronic inflammatory skin disease affecting 2-3% of the world population (1,2). Despite extensive studies, details of the disease mechanism remain to be elucidated.…”

Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis

“…Psoriasis affects between 1% and 3% of the U.S. population, an estimated 4.5-7.5 million Americans. 7 Of these persons, approximately one-third suffer from moderate to severe disease that can not be controlled by topical therapies. 8 Total direct and indirect health care costs of psoriasis are calculated at $11.25 billion annually in the United States.…”